FibroGen (FGEN)
(Delayed Data from NSDQ)
$1.30 USD
+0.02 (1.56%)
Updated May 24, 2024 03:59 PM ET
After-Market: $1.31 +0.01 (0.77%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
FGEN 1.30 +0.02(1.56%)
Will FGEN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for FGEN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FGEN
Zoetis (ZTS) Beats Q1 Earnings and Revenue Estimates
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
FGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why You Should Add Immunovant (IMVT) to Your Portfolio
Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
Other News for FGEN
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting
FibroGen announces interim Phase 1b data presentation for FG-3246 at ASCO
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
3 Penny Stocks to Watch Now